Iatrogenic hypercalcemia in hemodialysis patients

Area of Science:

• Nephrology
• Mineral and Bone Disorder

Background:

• Calcium carbonate is a common phosphorus binder for hemodialysis patients.
• Hypercalcemia is a frequent side effect of high-dose calcium carbonate therapy.
• The interaction between calcitriol and calcium supplements regarding hypercalcemia risk is not well-established.

Purpose of the Study:

• To investigate the relationship between serum calcium levels, calcitriol use, calcium therapy, and parathyroid hormone (PTH) levels in hemodialysis patients.
• To assess the risk of hypercalcemia in hemodialysis patients receiving both calcitriol and calcium supplements.

Main Methods:

• Retrospective chart review of 74 hemodialysis patients (119 patient-dialysis years).
• Analysis of serum calcium, calcitriol dosage, calcium therapy, and PTH levels.
• Statistical analysis to determine the association between variables and hypercalcemia.

Main Results:

• 38% of patients experienced hypercalcemia at some point.
• Calcitriol therapy significantly increased hypercalcemia risk, independent of calcium therapy (p = 0.032).
• Patients on lower calcitriol doses had a higher risk of hypercalcemia and lower PTH levels, indicating less severe hyperparathyroidism.

Conclusions:

• Hypercalcemia is a common complication in hemodialysis patients treated with calcitriol and calcium carbonate.
• Lower calcitriol doses may increase hypercalcemia risk, necessitating careful dose titration.
• Further research is needed to determine optimal dialysate calcium levels to mitigate hypercalcemia without exacerbating hyperparathyroidism.